Evaluation of organ and tumour perfusion by contrast-enhanced ultrasound after transarterial chemoembolization because hepatocellular carcinoma
Recruiting
- Conditions
- C22.0Liver cell carcinoma
- Registration Number
- DRKS00016987
- Lead Sponsor
- niversitätsklinikum FrankfurtMedizinische Klinik 1
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 174
Inclusion Criteria
HCC under Treatment with TACE; Age over 18 years; informed consent.
Exclusion Criteria
Pregnancy, breast feeding; suspicion of allergy to Sonovue®; heart insufficiency NYHA III-IV; acute coronary syndrome or unstable Angina pectoris in the last 7 days; cardiac dysrhythmia; acute heart failure; pulmonary Hypertension (PAP> 90mmHg); cardiac Shunts; high blood pressure; dyspnea.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of the target lesion with CEUS after TACE (real time contrast enhancement of the lesion and the liver)
- Secondary Outcome Measures
Name Time Method Assessment of abdominal side effects after TACE